Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROUS OXIDE, USP vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitrous oxide is an inhalational anesthetic with analgesic, anxiolytic, and amnestic properties. It acts as a non-competitive NMDA receptor antagonist, inhibits GABA-A receptors, and modulates opioid receptors, leading to altered neurotransmission and dissociation.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Anesthesia induction and maintenance,Procedural sedation and analgesia,Off-label: labor analgesia, treatment of severe pain in emergency settings
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Inhalation: 25-75% nitrous oxide in oxygen for sedation; 50-70% for anesthesia, titrated to effect.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life is 2–6 minutes (context-sensitive); rapid washout due to low blood solubility and high pulmonary elimination.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Nitrous oxide is metabolized minimally (approximately 0.004%) via intestinal bacterial reduction to free radicals and nitrogen. Pulmonary excretion unchanged accounts for >99% of elimination.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily eliminated via lungs as unchanged gas (>99% exhaled); negligible renal (<1%) or biliary/fecal elimination.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
<0.5% (minimally bound; essentially unbound in plasma).
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
0.5–1.0 L/kg (rapid distribution to vessel-rich tissues; maintains rapid onset and offset).
4-6 L/kg; large Vd indicates extensive tissue distribution
Inhalation: 100% (administered as gas; absorbed directly across alveolar membrane).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
No dose adjustment required; nitrous oxide is minimally excreted renally.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No dose adjustment required; metabolism is minimal.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Inhalation: 5-50% nitrous oxide in oxygen, titrated to effect; for anesthesia, up to 70%.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Decrease concentration and titrate slowly due to increased sensitivity; monitor for hypotension and hypoxia.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Nitrous oxide may cause megaloblastic anemia and neurological complications with prolonged use (e.g., >24 hours) due to inactivation of vitamin B12 and folate deficiency. Monitor for signs of B12 deficiency.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of hypoxia due to diffusion hypoxia upon discontinuation; oxygen supplementation required. May cause bone marrow suppression, B12 deficiency neuropathy, and impaired vitamin B12-dependent enzyme activity. Use caution in patients with pre-existing neurological disease, hematologic disorders, or vitamin B12/folate deficiency. Chronic exposure can lead to reproductive toxicity and occupational hazard.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Absolute: Known hypersensitivity, severe hematologic abnormalities (e.g., megaloblastic anemia), active vitamin B12 deficiency, need for prolonged oxygen therapy (e.g., pneumothorax, bowel obstruction), air trapping conditions (e.g., middle ear surgery, sinus infection). Relative: Pregnancy (first trimester), neurological disease, folate deficiency.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No specific food interactions. However, patients with vitamin B12 deficiency or those on methotrexate should ensure adequate B12 and folate intake; nitrous oxide can deplete B12 stores. Heavy meals before sedation may increase risk of aspiration and nausea.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Nitrous oxide is classified as FDA Pregnancy Category C. First trimester: In vitro and animal studies suggest potential teratogenicity at high concentrations; limited human data show no increased risk of major malformations with brief, low-dose exposure. Second/third trimesters: Use is generally considered safe for short durations; prolonged or repeated exposure may reduce uterine blood flow and cause fetal hypoxia. There is no evidence of increased congenital anomalies from routine use in dentistry or surgery.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Nitrous oxide is rapidly eliminated from plasma; low levels may pass into breast milk. No published M/P ratio. After a single dose, breastfeeding can be resumed once the mother is alert and has recovered from anesthesia. Limited data suggest no adverse effects on nursing infants. Caution with repeated or high doses.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No dose adjustments are typically required for short-term use. However, due to increased minute ventilation and decreased functional residual capacity in pregnancy, onset of action may be faster and depth of anesthesia may be greater. Consider using lower inspired concentrations (e.g., 30-50% N2O in O2) to avoid maternal hypoxia. Avoid prolonged exposure to reduce risk of fetal hypoxia and methemoglobinemia.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Nitrous oxide has a rapid onset (30-60 seconds) and offset; monitor for diffusion hypoxia upon discontinuation by administering 100% oxygen for 3-5 minutes. Avoid in patients with pneumothorax, bowel obstruction, middle ear surgery, or intracranial air due to risk of expansion. Use with caution in patients with vitamin B12 deficiency or methylenetetrahydrofolate reductase (MTHFR) mutations due to inactivation of methionine synthase. Nitrous oxide is a potent analgesic but weak anesthetic; always combine with an amnestic agent (e.g., benzodiazepine) for procedural sedation. In pediatric patients, use 30-50% concentration; higher concentrations may cause vomiting or excitement. Check waste gas scavenging systems to prevent occupational exposure.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
You may feel lightheaded, euphoric, or have tingling sensations; this is normal and will resolve quickly after stopping the gas.,You will receive oxygen after the procedure to prevent a sudden drop in oxygen levels.,Do not eat a heavy meal for 2-3 hours before sedation to reduce the risk of nausea or vomiting.,Inform your healthcare provider if you have a history of vitamin B12 deficiency, anemia, or lung problems (e.g., pneumothorax).,You should not drive, operate machinery, or make important decisions for 24 hours after sedation.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"The concurrent administration of nitrous oxide and bupivacaine may increase the risk of cardiovascular depression and arrhythmias due to synergistic cardiovascular depressant effects. Nitrous oxide can cause sympathetic nervous system activation and myocardial depression, while bupivacaine prolongs ventricular depolarization and increases the risk of reentrant arrhythmias, particularly at high doses. This combination may lead to hypotension, bradycardia, or more severe cardiac conduction abnormalities, especially in patients with preexisting cardiac disease."
"Nitrous oxide, an NMDA receptor antagonist and anesthetic gas, can enhance the central nervous system (CNS) depressant effects of difenoxin, an opioid antidiarrheal that acts on mu-opioid receptors. This combination increases the risk of profound sedation, respiratory depression, and coma, particularly in elderly or debilitated patients. Concurrent use may also exacerbate hypotension and bradycardia due to synergistic effects on the autonomic nervous system."
"Nitrous oxide (N2O) is an NMDA receptor antagonist and can inhibit the enzyme methionine synthase, leading to decreased methionine and increased homocysteine levels. Lamotrigine, a sodium channel blocker and glutamate release inhibitor, has proconvulsant effects at high doses and can lower the seizure threshold. The combination may increase the risk of seizures and neurotoxicity, particularly in patients with underlying epilepsy or rapid dose escalation of lamotrigine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROUS OXIDE, USP vs ABSTRAL, answered by our medical review team.
NITROUS OXIDE, USP is a Inhalational Anesthetic that works by Nitrous oxide is an inhalational anesthetic with analgesic, anxiolytic, and amnestic properties. It acts as a non-competitive NMDA receptor antagonist, inhibits GABA-A receptors, and modulates opioid receptors, leading to altered neurotransmission and dissociation.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROUS OXIDE, USP and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROUS OXIDE, USP is: Inhalation: 25-75% nitrous oxide in oxygen for sedation; 50-70% for anesthesia, titrated to effect.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROUS OXIDE, USP and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROUS OXIDE, USP is classified as Category C. Nitrous oxide is classified as FDA Pregnancy Category C. First trimester: In vitro and animal studies suggest potential teratogenicity at high concentrations; limited human data sh. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.